Innovent Biologics subsidiary Altruist Biologics receives NMPA acceptance for a new drug application, validating its localized manufacturing platform and CDMO operational strategy.
Innovent Biologics' subsidiary, Altruist Biologics, has achieved a significant regulatory milestone with the NMPA's acceptance of an NDA for localized manufacturing. This development validates the operational capabilities of the Altruist CDMO platform, directly enhancing the parent company's integrated biopharmaceutical supply chain and manufacturing efficiency in the Chinese market.
Altruist Biologics is a wholly owned subsidiary of Innovent Biologics (1801.HK) and functions as its CDMO arm.
The company received NMPA acceptance for an NDA related to localized manufacturing, supported by its CMC platform.
Innovent Biologics subsidiary Altruist Biologics secured NMPA acceptance for a new drug application, marking a significant regulatory milestone for its localized manufacturing platform. This development strengthens the company's CDMO capabilities and bolsters its long-term production pipeline in the Chinese market.
The acceptance validates the CMC platform of its subsidiary, Altruist Biologics, confirming that its localized manufacturing processes meet regulatory standards for drug development.